With Omzo, the most important care-delivery question is not simply what medication appears on the homepage. It is who becomes responsible after each step: the platform collecting your questionnaire, the clinician evaluating you, the pharmacy preparing medication and the team answering a later concern. Omzo explicitly says it is neither a medical practice nor a pharmacy. Its service therefore needs to be understood as a series of handoffs, rather than one organization directly providing every part of treatment.
Public documentation consulted October 19, 2026 describes initial screening, outside clinical evaluation, medication packages, shipping and ongoing support. That provides a useful outline, but not a complete operating picture. The consulted pages do not identify the clinical networks or dispensing pharmacies by name, establish comparable monthly costs or explain a reliable follow-up schedule. This review traces the documented journey and highlights the details a prospective patient would need confirmed before paying, sharing additional medical information or relying on a delivery estimate.
At a glance
- Care structure
- Omzo says it does not employ healthcare providers or directly provide medication; outside clinical networks make prescribing decisions.Sources: [7]
- Initial handoff
- Omzo collects qualifying information, then an outside healthcare provider may invite the patient to schedule through a portal Omzo does not operate.Sources: [3]
- Primary medication pathway
- The platform says its primary program uses compounded medications prepared and shipped by a state-licensed sterile compounding pharmacy; the consulted pages do not name that pharmacy.Sources: [7]
- Prices lack a defined interval
- Terms list GLP-1 follow-up at $299 and compounded tirzepatide follow-up at $399, but do not establish supply duration or billing frequency.Sources: [4]
- Shipping milestone
- Terms say compounded medication will ship within the next 48 business hours after prescription approval during the telehealth consultation. That is dispatch, not arrival.Sources: [4]
Start by separating the platform from the treating clinician
Omzo’s privacy notice identifies the business as Omzo Inc. Its homepage draws a clear boundary around that business: Omzo is not a medical practice or pharmacy, does not employ healthcare providers and does not directly provide medication. Clinical services instead come through third-party networks that Omzo describes as comprising U.S.-licensed clinicians. Those descriptions are provider statements, not independent verification of the credentials or availability of an individual practitioner.
That separation matters because completing Omzo’s website assessment does not itself create a doctor–patient relationship. The outside clinician determines eligibility using medical history and professional assessment, and makes the final prescribing decision. The practical question is when a named treating professional takes responsibility—not merely when the platform accepts a questionnaire. Our explanation of platform and clinician responsibilities provides context for understanding that distinction.
The consulted pages do not name the clinical networks, individual clinicians or pharmacies a patient would encounter. There is also a documentation tension: Omzo’s HIPAA policy uses treatment-oriented language, while other pages place diagnosis and treatment with outside providers. This does not establish that care is unavailable, but it makes written confirmation of the treating organization and its contact details particularly useful before enrollment.
The intake moves into a separate clinical portal
Omzo describes a two-stage intake rather than a single website form that completes the clinical evaluation. It collects initial qualifying information and passes that information to a healthcare provider. If appropriate, that provider invites the person to schedule an initial appointment through its own patient portal, which Omzo does not operate. The provider then requests additional medical and personal information and supplies the consultation, diagnosis and treatment.
The privacy policy gives a specific instruction for that transition: after the initial brief Omzo questionnaire, patients should provide health or medical information only through the healthcare provider’s sites. A prospective patient should therefore establish which portal is the clinical record and where messages about symptoms or treatment belong. The first-consultation preparation guide can help organize questions without treating the platform’s screening form as a completed medical assessment.
The service is intended for adults 18 or older. Terms restrict products and services to the 50 U.S. states and exclude other territories and countries, but this does not verify effective clinical availability in every state. Public documentation does not specify Omzo’s BMI criteria, required laboratory work, appointment wait times or language assistance. These are open operational questions, not reasons to assume a particular person will qualify or be declined.
Confirm the actual product at the pharmacy handoff
Omzo says its primary program provides compounded medications prepared and shipped by a state-licensed sterile compounding pharmacy. It also says the facilities producing compounded products are FDA registered. Neither statement identifies the dispensing pharmacy in the consulted documentation, and facility registration is not FDA approval of a medication. The exact formulation, concentration, presentation and route that a particular patient would receive are not established across the advertised offerings.
The site also advertises customized daily oral medication kits without identifying their ingredients in the consulted description. Those kits should not be assumed to contain a particular GLP-1 ingredient or to be interchangeable with an injectable product. Before fulfillment, the useful checkpoint is a written product description and a named pharmacy. Our guide to the prescription-to-pharmacy handoff explains why those details matter beyond an ingredient name on a promotional card.
Omzo’s terms acknowledge that compounded medications are not FDA approved and do not undergo FDA review for safety, effectiveness or quality. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Nonapproval alone does not establish clinical inequivalence. Omzo separately disclaims claims that its compounded formulations are equivalent to, share the same active ingredient as, or produce the same outcomes as an approved drug.
Package prices do not establish a monthly care schedule
Omzo publishes prices, but the pages do not establish a consistent billing interval or medication supply duration. The homepage’s semaglutide card says “Starting at $179,” and its tirzepatide card says “Starting at $279.” Terms instead describe initial consultation packages as “Originally priced” at $179 for GLP-1 and $259 for GLP-1 + GIP. The difference between the two initial tirzepatide figures is unresolved; neither should be silently substituted for the other.
The terms say the consultation packages include telehealth consultation, prescription, medication, shipping and ongoing medical support if needed. The GLP-1 + GIP packages specifically identify compounded tirzepatide; the general GLP-1 package does not provide equivalent product detail. A listed prescription component remains subject to the clinician’s decision. These package descriptions do not establish a month of medication, a minimum commitment or the timing of the next charge.
Omzo says medication costs are included in the fees it collects and that it pays the pharmacies. Transactions are in U.S. dollars, with MasterCard, Visa, American Express and Discover listed as payment methods. It says it does not store card details. Insurance billing, prior authorization assistance and HSA/FSA acceptance are not documented. Before payment, request the exact product, covered quantity, next billing date and any separate charges rather than converting these figures into an assumed monthly rate.
| Listing | Published amount | Documented scope or limitation |
|---|---|---|
| Homepage semaglutide card | Starting at $179 | Supply period, route and presentation not specified in the cited listing. |
| Homepage tirzepatide card | Starting at $279 | Relationship to the terms’ initial $259 figure is unexplained. |
| Initial GLP-1 consultation | Originally priced at $179 | Consultation, prescription, GLP-1 medication, shipping and support if needed; supply duration unspecified. |
| Follow-up GLP-1 consultation | $299 | Same listed service categories; billing frequency unspecified. |
| Initial GLP-1 + GIP consultation | Originally priced at $259 | Includes compounded tirzepatide and listed consultation services; supply duration unspecified. |
| Follow-up GLP-1 + GIP consultation | $399 | Includes compounded tirzepatide and listed consultation services; billing frequency unspecified. |
Branded prescriptions have a conflicting fulfillment pathway
For branded medication, Omzo’s general disclosure describes a different arrangement from its main compounded program. It says Omzo does not sell, dispense or ship branded medications. If a clinician prescribes one, the patient is responsible for filling the prescription at a chosen pharmacy and paying all associated costs. That description puts the pharmacy selection and purchase outside the platform’s ordinary included-medication pathway.
The terms, however, describe limited exceptions in which Omzo manages dispensing and shipping of FDA-approved branded medications. Availability is not guaranteed and depends on clinical approval and inventory, with all associated costs assigned to the patient. These statements conflict about who handles fulfillment. The public documentation does not resolve whether a particular prescription would follow the chosen-pharmacy route or an exception managed through Omzo.
Before relying on branded access, obtain a written explanation covering the exact product, prescription destination, dispensing pharmacy, separate medication price and who handles an unavailable product. The package’s general medication-included language should not be treated as overriding the specific patient-paid branded disclosures. Likewise, the mention of branded exceptions is not evidence of guaranteed inventory, insurance coverage or a prescription for any individual.
Shipping begins after approval, not after completing intake
Omzo’s terms place the compounded-medication shipping milestone after prescription approval during the telehealth consultation. They say medication will be shipped within the next 48 business hours. This is a dispatch statement, not a promise of arrival within two days, and it does not include the time needed to arrange or complete clinical evaluation. No carrier, tracking process or destination-specific arrival estimate is established in the consulted pages.
The homepage advertises free, discreet delivery on all treatments and describes plain packaging. Terms say shipping cannot be canceled or modified after dispatch. Those promises and restrictions make address confirmation important before fulfillment, especially because the pages do not explain replacement procedures for loss, damage or delivery problems. Free delivery also does not make treatment free; medication and clinical service charges remain part of the package or applicable branded arrangement.
Cold-chain handling is another undocumented operational detail. FDA explicitly advises patients not to use an injectable GLP-1 drug that arrives warm or with insufficient refrigeration, and to contact the provider or dispensing pharmacy. That guidance is not a finding about Omzo’s shipments. Before ordering an injectable, identify the pharmacy contact and problem-reporting process; our guide to warm injectable deliveries explains the FDA advice without offering dosing instructions.
Ongoing support is advertised, but its operating details are limited
Omzo promotes fast virtual consultations, clinician-reviewed plans, supplements delivered to the home and ongoing support through its app. It also describes a care team accessible by message. Package terms include ongoing medical support “if needed.” Together, these statements document an intended support channel, but they do not establish response times, hours of operation, a scheduled monitoring cadence or whether every message reaches the prescribing clinician.
Weight plans may include prescribed medication, nutrition guidance and daily habits aimed at long-term balance. The conditional wording matters: it does not guarantee every component in every plan. NIDDK describes follow-up as involving treatment response and tolerability, not simply renewed payment. For Omzo, patients should clarify who reviews those issues, how follow-up consultations are arranged and when another package charge becomes necessary.
Contact details also need confirmation. The contact page lists 6192 Coastal Highway, Lewes, Delaware 19958, while the HIPAA policy lists 16192 Coastal Highway and telephone number (332) 301-2274. Email addresses were not available in usable form in the consulted text. Separately, the privacy policy permits certain health-data uses for service operations, advertising and marketing, and legal matters, subject to applicable law and consent where required; patients should review that alongside the outside provider’s privacy practices.
Understand the financial boundary before submitting medical intake
Omzo’s refund boundary arrives earlier than medication dispatch. For prescription medication orders, terms consider the order processed and nonrefundable once the initial medical intake has been submitted, subject to stated exceptions. Supplement orders become processed and nonrefundable upon payment. These are distinct triggers; neither should be replaced with an assumption that cancellation remains available until a package leaves the pharmacy.
The terms provide a full refund when the clinician determines during the initial consultation that a patient is medically ineligible. That exception does not apply when a disqualifying condition was knowingly omitted or misrepresented in the initial questionnaire, under the conditions described in the policy. Full refunds are also stated for Omzo processing mistakes such as duplicate or incorrect charges. These are specific exceptions, not a general satisfaction guarantee.
Refund requests must be made within 28 days of payment, but the channel language conflicts: it initially allows email or physical mail, then says channels other than email will not be honored. Cancellation after a processed subscription charge prevents future charges but does not refund that charge. The practical cancellation method, advance-notice requirement and billing cadence are not established. Obtain a usable written contact and cancellation instructions before entering a recurring arrangement.
Questions & answers
Does completing Omzo’s assessment guarantee a prescription?
No. Omzo says its website assessment does not create a doctor–patient relationship. Initial information goes to an outside healthcare provider, which may invite you to schedule through its separate portal. A clinician reviews medical history and determines whether prescribing is appropriate. The consulted pages do not establish a guaranteed appointment time, prescription or medication choice.
Is Omzo’s $179 listing a monthly semaglutide price?
The documentation does not establish that. The homepage advertises semaglutide starting at $179, while terms describe an initial GLP-1 package as originally priced at $179 and a follow-up package at $299. Supply duration and billing intervals are unspecified. Ask for the exact medication, formulation, route, quantity and next charge date before treating any figure as a recurring cost.
Which pharmacy prepares Omzo’s compounded medication?
The consulted pages do not name it. Omzo describes a state-licensed sterile compounding pharmacy that prepares and ships medication, and says it pays pharmacies from collected fees. Request the dispensing pharmacy’s name and contact information before fulfillment, along with the product description. The platform’s statements about licensing and facility registration were not independently verified in this review.
Will Omzo ship a branded medication if one is prescribed?
Its public pages give conflicting answers. A general disclosure says patients fill branded prescriptions at their chosen pharmacy and pay the costs. Terms describe limited exceptions in which Omzo manages dispensing and shipping, subject to clinical approval and inventory, also at the patient’s expense. Confirm the applicable pathway in writing; neither statement guarantees branded availability.
How quickly should an approved order arrive?
Omzo does not establish an arrival deadline in the consulted terms. Its statement concerns shipping within the next 48 business hours after prescription approval during consultation. Appointment scheduling and transit are separate periods. The documentation also does not detail tracking, refrigeration procedures or replacements. Ask for a shipment-specific estimate and the pharmacy’s delivery-problem contact rather than interpreting dispatch as delivery.
Can I cancel after submitting intake and receive my money back?
Not automatically. Terms generally make prescription orders nonrefundable after initial medical intake, with exceptions including qualifying medical ineligibility and Omzo billing errors. Subscription cancellation stops future charges but does not reverse processed charges. Refund requests have a 28-day deadline, and the stated submission channels conflict. Confirm cancellation instructions and a working refund contact before paying.
Our assessment
Omzo documents a potentially convenient coordinated pathway: initial online screening, outside clinical evaluation, bundled compounded-medication packages and home shipping with advertised app support. Its clearest limitation is not an absence of services, but an incomplete account of who delivers them and on what timetable. Named clinicians and pharmacies, exact products, supply quantities, renewal dates and support responsibilities remain important confirmation points. Conflicting branded-fulfillment rules and refund contact instructions add practical uncertainty. Before enrolling, obtain one written explanation connecting the clinical portal, dispensing pharmacy, full payment schedule and cancellation process. That would make the advertised pathway easier to evaluate without assuming either guaranteed access or dependable continuity from the homepage alone.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.